Mode
Text Size
Log in / Sign up

FSP1 acts as an endogenous inhibitor of endothelial ferroptosis and vascular leakage in sepsisNew research identifies protein pathways that may protect against sepsis

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that FSP1 acts as an endogenous inhibitor of ferroptosis, but its clinical efficacy as a treatment is not yet tested.

This systematic review synthesizes the role of Ferroptosis Suppressor Protein 1 (FSP1) in the context of sepsis and associated organ injury. The authors focus on FSP1's mechanism of action, which involves inhibiting ferroptosis through the FSP1-CoQ10-NAD(P)H axis, the vitamin K cycle, ESCRT-III-mediated membrane repair, and a vitamin B2-dependent metabolic stability pathway.

Furthermore, the review highlights the STING-FSP1 signaling axis. Specifically, cGAS-STING activation transcriptionally represses FSP1, which is linked to increased endothelial ferroptosis and vascular leakage. These findings suggest that FSP1 serves as a critical endogenous inhibitor in these processes.

A primary limitation of this evidence is that it is a review article with no primary data provided; therefore, the clinical efficacy of FSP1 as a treatment has not been tested. Potential therapeutic strategies to target these pathways include Nrf2 activation and STING inhibition. Clinical application remains theoretical at this stage.

How this fits prior evidence

This systematic review addresses a gap in understanding the molecular mechanisms of sepsis-induced vascular leakage. While prior coverage identified biomarkers like plasma ANXA3 for predictive accuracy and clinical indicators such as Mottling Score, CRT, and PPI to correlate with mortality, this review focuses on the underlying biochemical pathways involving FSP1. It does not directly relate to previous findings regarding tachypnoea in infants or IgM-enriched immunoglobulin.

Sepsis is a life-threatening reaction to infection that can cause rapid organ failure. Researchers are looking closely at why some patients suffer more severe tissue damage than others, specifically focusing on a process called ferroptosis. This is a type of cell death triggered by iron and oxidative stress.

A specific protein called FSP1 acts as a natural shield against this cell death. The research shows that when certain signals in the body are activated, they can turn off FSP1. When FSP1 is suppressed, it leads to damaged blood vessels and organ injury. By understanding these pathways, scientists hope to find better ways to protect patients.

Because this is a review of existing scientific literature rather than a clinical trial, we do not yet know how well these findings work in humans. The study identifies potential targets for future treatments, such as using specific inhibitors to keep the FSP1 protein active and protect the body during a severe infection.

What this means for you:
The FSP1 protein helps prevent cell death and organ damage during sepsis by protecting blood vessels.

Common questions

What is the role of FSP1 in sepsis?

FSP1 is a protein that acts as an endogenous inhibitor, meaning it naturally helps stop a type of cell death called ferroptosis. In the context of sepsis, keeping this protein active can help prevent damage to blood vessels and nearby organs.

How does the body cause damage during sepsis?

When certain signals in the body are activated, they can repress the FSP1 protein. This loss of protection leads to endothelial ferroptosis, which causes blood vessels to leak and organs to become injured during a severe infection.

Are there new treatments available for sepsis based on this?

This study is a review of existing research rather than a clinical trial. While it identifies potential strategies like Nrf2 activation or STING inhibition to protect the FSP1 pathway, these have not been tested as treatments in humans yet.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, remains a global health challenge characterized by high mortality and limited therapeutic options. Recent evidence identifies ferroptosis—an iron-dependent form of regulated cell death driven by the lethal accumulation of lipid peroxides—as a pivotal mechanism underlying sepsis-induced organ damage. Ferroptosis Suppressor Protein 1 (FSP1) has emerged as a critical endogenous inhibitor of ferroptosis that operates independently of the canonical GPX4/glutathione system. This review provides a comprehensive overview of recent research on FSP1 in the context of sepsis-associated organ injury. We detail the multifaceted molecular mechanisms through which FSP1 inhibits ferroptosis, including the canonical FSP1-CoQ10-NAD(P)H axis, the non-canonical vitamin K cycle, ESCRT-III-mediated membrane repair, and the newly characterized vitamin B2-dependent metabolic stability pathway. Furthermore, we highlight the newly discovered STING-FSP1 signaling axis, where cGAS-STING activation transcriptionally represses FSP1, thereby driving endothelial ferroptosis and vascular leakage during sepsis. Additionally, potentially conserved pathways extrapolated from other acute injury models (e.g., ALKBH5, CD36, and SENP3) are discussed to propose novel research directions. The organ-specific roles and protective mechanisms of FSP1 in sepsis-induced injuries of the lungs, heart, liver, kidneys, and brain are systematically summarized. Finally, we evaluate the prospects and challenges of targeting FSP1-related pathways, such as Nrf2 activation and STING inhibition, as potential therapeutic strategies for sepsis. Overall, This review aims to provide new insights into the “inflammation-cell death” cascade in sepsis and offer a theoretical foundation for developing FSP1-targeted interventions to suppress ferroptosis.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.